research chemical comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-31. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Most reptiles, as well as birds, possess a nictitating membrane, a translucent third eyelid which is drawn over the eye from the inner corner. In crocodilians, it protects its eyeball surface while allowing a degree of vision underwater. However, many squamates, geckos and snakes in particular, lack eyelids, which are replaced by a transparent scale. This is called the brille, spectacle, or eyecap. The brille is usually not visible, except for when the snake molts, and it protects the eyes from dust and dirt.
A person, who is independent of the trial, who cannot be unfairly influenced by people involved with the trial, who attends the informed consent process if the subject or the subject's legally acceptable representative cannot read, and who reads the informed consent form and any other written information supplied to the subject. (ICH E6) In vitro
In his memoir I'm Not the Only One (2004), Galloway wrote:"Just as Stalin industrialised the Soviet Union, so on a different scale Saddam plotted Iraq's own Great Leap Forward. ... He managed to keep his country together until 1991. Indeed, he is likely to have been the leader in history who came closest to creating a truly Iraqi national identity, and he developed Iraq and the living, health, social and education standards of his own people." In the book, Galloway also expressed the opinion that Kuwait, which Iraq invaded, is "clearly a part of the greater Iraqi whole, stolen from the motherland by perfidious Albion". Christopher Hitchens responded that the state existed before Iraq had a name. The massacres of Kurds and Shias after the 1991 Gulf War, was according to Galloway, "a civil war that involved massive violence on both sides". In 2006 a video surfaced showing Galloway greeting Uday Hussein, Saddam's eldest son, with the title of "Excellency", at Uday's palace in 1999. Galloway is heard saying he will be with Uday "until the end". Galloway continued to praise Iraq's prime minister under Saddam, Tariq Aziz. In April 2005, on Al Jazeera during that year's general election campaign, he described Aziz as "an eminent diplomatic and intellectual person". In his opinion, Aziz was "a political prisoner" and advocated his release.
Sources: en.wikipedia.org
The hepatocyte is a complex and multifunctional differentiated cell whose cell response will be influenced by the zone in hepatic lobule, because concentrations of oxygen and toxic substances present in the hepatic sinusoids change from periportal zone to centrilobular zone10. The hepatocytes of the intermediate zone have the appropriate morphological and functional features since they have the environment with average concentrations of oxygen and other substances. This specialized cell is capable of:
For decades after Libby performed the first radiocarbon dating experiments, the only way to measure the 14C in a sample was to detect the radioactive decay of individual carbon atoms. In this approach, what is measured is the activity, in number of decay events per unit mass per time period, of the sample. This method is also known as "beta counting", because it is the beta particles emitted by the decaying 14C atoms that are detected. In the late 1970s an alternative approach became available: directly counting the number of 14C and 12C atoms in a given sample, via accelerator mass spectrometry, usually referred to as AMS. AMS counts the 14C/12C ratio directly, instead of the activity of the sample, but measurements of activity and 14C/12C ratio can be converted into each other exactly. For some time, beta counting methods were more accurate than AMS, but AMS is now more accurate and has become the method of choice for radiocarbon measurements. In addition to improved accuracy, AMS has two further significant advantages over beta counting: it can perform accurate testing on samples much too small for beta counting, and it is much faster – an accuracy of 1% can be achieved in minutes with AMS, which is far quicker than would be achievable with the older technology.
This manifests as "electrode saturation", loss of cyclable Ah charge and as a "voltage fade". Other material degradations. Negative copper current collector is particularly prone to corrosion/dissolution at low cell voltages. PVDF binder also degrades, causing the detachment of the electroactive materials, and the loss of cyclable Ah charge.
Sources: en.wikipedia.org
Leela Kapila, Consultant Paediatric Surgeon, University Hospital, Nottingham. For services to Medicine. Fergal Patrick Keane, BBC Foreign Correspondent. For services to Television Journalism. John Kelly. For services to Agriculture and to Banking. John Charles King, Chief Executive, Security Facilities Executive, Cabinet Office (Office of Public Service). John Kirkham, lately Grade 6, Ministry of Agriculture, Fisheries and Food. Glen Kirton. For services to Association Football, particularly Euro 96. Alice Elizabeth Audrey Lamb. For services to Education. Penelope Lambert. For services to the Board of Visitors Her Majesty's Prison Whitemoor. Michael John Leech, Principal, Stevenson College, Edinburgh. For services to Education. Gilberte-Marie Brunsdon-Lenaerts. For services to Anglo-Belgian Relations. Ann Molyneux Lewis, lately President, Royal Pharmaceutical Society of Great Britain. For services to the Pharmacy Profession. Kenneth Lewis, Chairman, Horizon NHS Trust. For services to Health Care. Timothy Lewis. For services to the Police. Ian Stanley Cash Linney. For services to the community in Nottinghamshire. James Logan. For services to Aviation. Angus Victor Peck MacKay, Physician Superintendent, Argyll and Bute Hospital. For services to Medicine. William Alexander Lee MacKay, Vice Chairman, Management and Human Resources Committee, Association of District Councils. For services to Local Government. Lieutenant Colonel John Pierce Margarson, . For services to Soldiers' Sailors' and Airmens' Families Association in Clwyd.
=== Guest stars === Adam J. Yeend as Danny Mendoza Dearbhla Molloy as Queen Isabel Adam Fergus as Prince Richard Hilty Bowen as Princess Emily Josh Brener as Gavin Price Julie Claire as Francesca Hunter William Russ as Frank Holland Denise Crosby as Janet Holland Brian White as Franklin Russell Jon Tenney as Andrew Nichols
=== Dextran nanoparticle applications === Dextran nanoparticles have advantages such as increased drug-loading capacity, improved cellular uptake, reduce off-site toxicity, and increase local drug concentrations at the target tissue site. The current research indicates that dextran nanoparticles can potentially have applications in the delivery of anti-tumor therapeutics.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.